These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 24889848)

  • 21. [Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
    Darius H
    Dtsch Med Wochenschr; 2020 Jul; 145(14):978-986. PubMed ID: 32668469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis.
    Huang WY; Singer DE; Wu YL; Chiang CE; Weng HH; Lee M; Ovbiagele B
    JAMA Neurol; 2018 Dec; 75(12):1511-1518. PubMed ID: 30105396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Safety and Efficacy of Eight Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Liang B; Zhu YC; Gu N
    Front Cardiovasc Med; 2022; 9():832164. PubMed ID: 35387437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2.
    Fernandez MM; Wang J; Ye X; Kwong WJ; Sherif B; Hogue S; Sherrill B
    SAGE Open Med; 2015; 3():2050312115613350. PubMed ID: 27092254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
    Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
    J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Approaches for Stroke Prophylaxis in Patients with Non-Valvular Atrial Fibrillation: Network Meta-Analyses of Randomized Controlled Trials.
    Bajaj NS; Kalra R; Patel N; Hashim T; Godara H; Ather S; Arora G; Pasala T; Whitfield TT; McGiffin DC; Ahmed MI; Lloyd SG; Limdi NA; Arora P
    PLoS One; 2016; 11(10):e0163608. PubMed ID: 27706224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis.
    Lee KH; Chen YF; Yeh WY; Yeh JT; Yang TH; Chou CY; Chang YL; Wang WT; Chiang CE; Chen CH; Cheng HM
    Age Ageing; 2022 Dec; 51(12):. PubMed ID: 36571776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
    Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
    Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of antithrombotic agents for atrial fibrillation in older adults at risk for falls: a mathematical modelling study.
    Wong EKC; Belza C; Naimark DMJ; Straus SE; Wijeysundera HC
    CMAJ Open; 2020; 8(4):E706-E714. PubMed ID: 33158928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation.
    Tawfik A; Bielecki JM; Krahn M; Dorian P; Hoch JS; Boon H; Husereau D; Pechlivanoglou P
    Clin Pharmacol; 2016; 8():93-107. PubMed ID: 27570467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
    Lane DA; Raichand S; Moore D; Connock M; Fry-Smith A; Fitzmaurice DA;
    Health Technol Assess; 2013 Jul; 17(30):1-188. PubMed ID: 23880057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
    J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
    Staerk L; Gerds TA; Lip GYH; Ozenne B; Bonde AN; Lamberts M; Fosbøl EL; Torp-Pedersen C; Gislason GH; Olesen JB
    J Intern Med; 2018 Jan; 283(1):45-55. PubMed ID: 28861925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Proietti M; Romanazzi I; Romiti GF; Farcomeni A; Lip GYH
    Stroke; 2018 Jan; 49(1):98-106. PubMed ID: 29167388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
    Deedwania PC; Huang GW
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.